Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Patent
1993-11-03
1998-04-07
Schwadron, Ronald B.
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
4241431, 4241441, 4241561, 4241741, 424800, 424801, 4241531, 4353201, 435328, 435334, 4353431, 4352523, 435 70, 435 72, 435 15, 435104, 5303873, 53038822, 53038873, 53038885, 530867, A61K 39395, C07K 1630, C12N 121, C12N 520
Patent
active
057361371
ABSTRACT:
Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, and cooperative strategies comprising the use of chimeric anti-CD20 antibodies and radiolabeled anti-CD20 antibodies.
REFERENCES:
patent: 5500362 (1996-03-01), Robinson et al.
"Antibody Shows Promise in Treating B-Cell Lymphoma" from: Cope-Working in Oncology, Mar./Apr. 1994.
Sally J. DeNardo et al, "The Biologic Window for Chimeric 1.6 Radioimmunotherapy", Cancer Supplement, vol. 73, No. 3, pp. 1023-1032, Feb. 1, 1994.
Mitchell E. Reff, "Depletion of B Cells In Vivo by a Chimeric Mouse Human Monoclonal Antibody to CD20", Blood, vol. 83, No. 2, pp. 435-445, Jan. 15, 1994.
Genetic Engineering News, "Developing Chimeric Monoclonals", vol. 5, No. 3, Mar. 1985.
Liu et al., "Production of a Mouse-Human Chimeric Monoclonal Antibody to DCD20 With Potent FC-Dependent Biologic Activity", Journal of Immunology, vol. 139, No. 10, 15 Nov. 1987, pp. 3521-3526.
Hekman et al., "Immunotherapy", The Netherlands Cancer Institute Amsterdam Annual Report 1993, pp. 47-48.
Reff et al., "Depletion of B Cells in Vivo by a Chimeric Mouse Human Monoclonal Antibody to CD20", Journal of Cellular Biochemistry, vol. 17, No. Supplement 17E, 29 Mar. 1993, p. 260.
Anderson, D.R. The Second Annual IBC International Conference on Antibody Engineering, Dec. 16-18, 1991.
Press, O.W. 69/2 Blood 584 (1987).
Robinson, R.R. 2 Hum. Antibod. Hybrid. 84 (1991).
Morrison, S.L. 81 PNAS 6851 (1984).
Boulianne, G.L. 312 Nature 643 (1984).
Neubeiger, M.D. 314 Nature 268 (1985).
Tan, L.K. 135 J. Immunol. 8564 (1985).
Sun, L.K. 5/1 Hybridoma 517 (1986).
Sahagan, B.G. 137 J. Immunol. 1066 (1986).
Munro, A. 312 Nature 597 (1984).
Marx 229 Science 455 (1985).
Morrison 229 Science 1202 (1985).
Grossbard, M.L. 80/4 Blood 863 (1992).
Clark, E. 82 PNAS 1766 (1985).
Robertson, M.J. 79/9 Blood 2229 (1992).
Nadler, L.M. The Lancet 427 (Aug. 25, 1984).
Golay, J.T. 135/6 J. Immunol. 3795 (1985).
Greenberger, J.S. 45 Can. Res. 758 (1985).
Nadler, L.M. 40 Can. Res. 3147 (1980).
Tedder, T.F. 141/12 J. Immunol 4388 (1988).
Einfeld, D.A. 7/3 The EMBO Journal 711 (1988).
Tedder, T.F. 135/2 J. Immunol. 973 (1985).
Tedder, T.F. 16 Eur. J. Immunol. 881 (1986).
Valentine, M.A. 264/19 J. Bio. Chem. 11282 (1989).
Ozato, K. 126/1 J. Immunol. 317 (1981).
Calvert, J.E. 21/4 Sem. Hema. 226 (1984).
Anderson, K.C. 63/6 Blood 1424 (1984).
Oettgen, H.C. 2/1 Hybridoma 17 (1983).
Lipton, J.M. 60/1 Blood 170a (Abs. 609) (1982).
Anderson, K.C. 69/2 Blood 597 (1987).
Adams, R.A. 27/1 Can. Res. 2479 (1967).
Adams, R.A. 28 Can. Res. 1121 (1968).
Smeland, E.B. 138/10 J. Immunol. 3179 (1987).
Nadler, L.M. 74 J. Clin. Invest. 332 (1984).
Bhan, A.K. 154 J. Exp. Med. 737 (1981).
Buchsbaum, D.J. 25 Int. J. Radiation Onc. Bio Phys. 629 (1993).
Buchsbaum, D.J. 50 Can. Res. Supp. 9935 (1990).
Buchsbaum, D.J. 18 Int. J. Radiation Onc. Bio Phys. 1033 (1990).
Schlom, J. 82/9 J.N.C.I. 763 (1990).
Wessel, B.W. 11/5 Med. Phys. 638 (1984).
Srivastava, S.C. 18/6 Nucl. Med. Biol. 589 (1991).
DeNardo, S.J. 1/1 Antibody, Immuno. & Radiopharm. 17 (1988).
Appelbaum, F.R. 5/5 Hem./Onc. Clinics of N.A. 1013 (1991).
Eary, J.F. 31/8 J. Nucl. Med. 1257 (1990).
Press, O.W. 7/8 J. Clin. Onc. 1027 (1989).
Goldenberg, D.M. 9/4 J. Clin. Onc. 548 (1991).
Anderson Darrell R.
Hanna Nabil
Leonard John E.
Newman Roland A.
Rastetter William H.
Idec Pharmaceuticals Corporation
Schwadron Ronald B.
LandOfFree
Therapeutic application of chimeric and radiolabeled antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic application of chimeric and radiolabeled antibodies , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic application of chimeric and radiolabeled antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-10301